Kopin Corporation has announced its financial results for the first quarter of 2025, showcasing a 5% increase in total revenues, which reached $10.5 million, compared to $10.0 million in the same period of 2024. Product revenues saw a modest 2% increase, while funded research revenues experienced a significant 37% rise. The company reported a net loss of $3.1 million for the first quarter of 2025, a considerable improvement from the $32.5 million net loss recorded in the first quarter of 2024. This previous year's figure included a $24.8 million reserve for litigation damages. Selling, General and Administration (SG&A) expenses were notably reduced to $4.7 million, down from $7.2 million in the first quarter of 2024, primarily due to a $2.9 million decrease in legal fees. Research and Development (R&D) expenses remained flat at $2.1 million. Kopin Corporation received approximately $28 million in orders for the first quarter of 2025, translating to a positive book-to-bill ratio of 2.8:1. The company reaffirmed its expectations for double-digit revenue growth in 2025 compared to 2024. CEO Michael Murray highlighted the continued strong order flow, emphasizing the demand for application-specific optical solutions across defense, industrial, and medical applications. As part of its operational strategy, Kopin is embarking on an aggressive automation plan aimed at enhancing quality, improving product margins, and maximizing facility utilization on a continuous basis without expanding manufacturing shifts.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。